OnKure Therapeutics (NASDAQ:OKUR) Announces Quarterly Earnings Results, Misses Estimates By $0.37 EPS

OnKure Therapeutics (NASDAQ:OKUR) announced its quarterly earnings data on Tuesday. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.37), FiscalAI reports.

OnKure Therapeutics Stock Performance

NASDAQ:OKUR traded down $0.08 during trading hours on Tuesday, hitting $4.52. The stock had a trading volume of 95,002 shares, compared to its average volume of 234,204. OnKure Therapeutics has a one year low of $1.70 and a one year high of $5.38. The company has a market cap of $61.81 million, a price-to-earnings ratio of -1.02 and a beta of 0.36. The business’s 50 day moving average is $4.04 and its 200-day moving average is $3.30.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. HC Wainwright cut their price objective on shares of OnKure Therapeutics from $34.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, March 16th. Finally, Weiss Ratings upgraded shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $27.00.

Institutional Trading of OnKure Therapeutics

Several hedge funds have recently bought and sold shares of OKUR. XTX Topco Ltd bought a new position in OnKure Therapeutics in the second quarter valued at approximately $25,000. Jane Street Group LLC acquired a new stake in shares of OnKure Therapeutics during the fourth quarter worth $56,000. Hsbc Holdings PLC bought a new stake in OnKure Therapeutics in the 4th quarter valued at $58,000. Barclays PLC lifted its position in OnKure Therapeutics by 4,286.8% in the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after acquiring an additional 26,621 shares in the last quarter. Finally, Rangeley Capital LLC acquired a new position in OnKure Therapeutics in the 2nd quarter worth $71,000. 90.98% of the stock is currently owned by institutional investors and hedge funds.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.